Erasca GAAP EPS of -$0.15 misses by $0.01
Erasca reported Q3 GAAP EPS of -$0.15, missing estimates by $0.01. The company's cash and marketable securities totaled $947.8 million as of September 30, 2026, up from $341.8 million at the end of 2025. Erasca believes its current cash position will support upcoming milestones.
How this was made
The 30-second read
Why it matters
The slight miss may cause short‑term price decline, but the company’s sizable cash balance may mitigate longer‑term concerns.
Market read
Earnings miss for a small‑cap biotech; potential short‑term downside.
What to watch
Strong cash position of $947.8 M could support upcoming milestones despite the EPS miss.
Background
Erasca Inc. (ERAS) released its Q3 earnings, reporting a GAAP EPS of -$0.15 versus consensus of -$0.14.
Ticker impact
Q3 GAAP EPS of -$0.15 missed consensus by $0.01.
likely downward pressure as investors price in the miss
The miss is modest but earnings surprises often move small‑cap stocks sharply in after‑hours trading.
Market effects
Minimal impact on the broader biotech/health‑tech sector.
Limited to US small‑cap investors.
Low
Counterpoint
The miss is within a narrow range; the stock may rebound if cash runway remains strong.
Key entities
- companyErasca Inc.
Biotech firm reporting Q3 earnings.

